Preferred Treatment for Stage I Seminoma: A Survey of Canadian Radiation Oncologists

Clinical Oncology

Volumn 18, Issue 9, 2006, Pages 693-695

  Huddart, R A ^a   Joffe, J K ^b  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b HUDDERSFIELD ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; CANADA; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER RISK; CANCER STAGING; CLINICAL EFFECTIVENESS; COLON CANCER; EDITORIAL; ESOPHAGUS CANCER; GERM CELL TUMOR; HEALTH SURVEY; HUMAN; LEUKEMIA; LONG TERM CARE; MEDICAL SPECIALIST; OCCUPATIONAL EXPOSURE; PANCREAS CANCER; PREDICTION; PRIORITY JOURNAL; RADIATION DOSE; SEMINOMA; SOLID TUMOR; STOMACH CANCER;

CANADA; CHEMOTHERAPY, ADJUVANT; HEALTH CARE SURVEYS; HUMANS; MALE; RADIATION ONCOLOGY; RADIOTHERAPY, ADJUVANT; SEMINOMA; TESTICULAR NEOPLASMS;

EID: 33749042561     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2006.08.002     Document Type: Editorial

References (10)

1. Fossa S.D., Horwich A., Russell J.M., et al. Optimal planning target volume for stage I testicular seminoma: a Medical Research Council randomized trial. Medical Research Council Testicular Tumor Working Group. J Clin Oncol 17 (1999) 1146
2. Jones W.G., Fossa S.D., Mead G.M., et al. Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I testicular seminoma: a report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328). J Clin Oncol 23 (2005) 1200-1208
3. Travis L., Curtis R., Storm H., et al. Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst 89 (1997) 1429-1439
4. Travis L.B., Fossa S.D., Schonfeld, et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 97 (2005) 1354-1365
5. Zagars G.K., Ballo M.T., Lee A.K., and Strom S.S. Mortality after cure of testicular seminoma. J Clin Oncol 22 (2004) 640-647
6. Bayley A., Warde P., Milosevic M., and Goospodarowicz M. Surveillance for stage I testicular seminoma. A review. Urol Oncol 6 (2001) 139-143
7. Warde P., Specht L., Horwich A., et al. Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol 20 (2002) 4448-4452
8. Oliver R.T., Mason M.D., Mead G.M., et al. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet 366 9482 (2005) 293-300
9. Sohaib S.A., Huddart R., Dearnaley D.P., Horwich A., and Husband J. Sensitivity of MRI scanning in the diagnosis of retroperitoneal disease in testicular germ cell tumour. 105th Annual ARRS Meeting. New Orleans, USA. AJR Am J Roentgenol 4 Suppl. (2005) 63
10. Alomary l, Samant R, Genest P, Eapen L, Gallant V. The preferred treatment for Stage I seminoma: a survey of Canadian radiation oncologists. Clin Oncol 2006;18:696-699.